

September 19, 2006

RE: Effectiveness of the rapid-acting and basal insulins

The use of rapid-acting and the two new (to Canada) extended long-acting insulins have markedly improved the lives of my patients, with Type 1 and Type 2 insulin-requiring Diabetes Mellitus, **for whom these insulins were affordable.**

These insulins, where used appropriately, have decreased the incidence of nocturnal, daytime and severe hypoglycemia alone or in combination in every person in whom I have used them.

In addition, my patients have enjoyed an improved quality of life whilst experiencing stabilizing of their blood sugar control, thusly reducing their risk for health care costly and personally devastating complications of Diabetes.

I strongly urge the Government of BC to provide full financial coverage for the use of Insulins Glargine and Detemir, Humalog and Novorapid urgently.

.
Dr C. Mahony MD, FRCP, Medical Director of SMH Diabetes Education Center, Member of FHA Diabetes Framework Committee